{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T02:19:59Z","timestamp":1787019599868,"version":"build-2736575974"},"reference-count":27,"publisher":"American Society of Hematology","issue":"24","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,12,23]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>High-grade B-cell lymphomas (HGBL, including double-hit\/triple-hit [HGBL-DH\/TH], and HGBL not otherwise specified) have a poor prognosis upon failure of first-line therapy. Anti-CD19 chimeric antigen receptor (CAR) T-cell therapy for third-line aggressive large B-cell lymphomas (LBCL) resulted in long-term remission in \u226440% of patients. This study evaluated factors that can predict outcomes in HGBL compared to diffuse LBCL (DLBCL). We assessed the predictive value of the subtype (HGBL vs DLBCL) using weighted log-rank tests and weighted Cox models, and overall survival (OS) following CAR T-cell therapy failure. The prospective study cohort comprised 432 patients (HGBL, n = 78; DLBCL, n = 354), median follow-up of 22.8 months for HGBL and 18 months for DLBCL. Interestingly, there was no statistically significant difference in progression-free survival and OS between patients with HGBL-DH\/TH lymphomas vs other high-grade histotypes. CAR T-cell therapy expansion in HGBL did not correlate with response. Before weighting, a significant difference in OS was observed between HGBL vs DLBCL (24-month OS: 37% vs 49%, P = .0036). After weighting, the difference in 2-year OS remained significant (37% vs 44%, P = .0343), and it was related to inferior survival following CAR T-cell therapy failure. The 2-year nonrelapse mortality and incidence of secondary malignancies were similar in patients with HGBL and DLBCL (11% vs 11%, P = .830; 6.4% vs 11.4%, P = .844). Among patients in whom CAR T-cell therapy failed, the 1-year OS after failure was significantly higher in transformed than de novo DLBCL and HGBL (59% vs 32% vs 11%, &amp;lt;0.0004). Earlier use of CAR T-cell therapy may improve the outcome of HGBL. This trial was registered at www.clinicaltrials.gov as #NCT06339255.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/bloodadvances.2025016117","type":"journal-article","created":{"date-parts":[[2025,8,5]],"date-time":"2025-08-05T19:06:52Z","timestamp":1754420812000},"page":"6491-6501","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":5,"title":["Outcomes of CAR T-cell therapy in high-grade B-cell lymphomas compared to DLBCL: a weighted comparison analysis"],"prefix":"10.1182","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0332-5412","authenticated-orcid":false,"given":"Anna","family":"Dodero","sequence":"first","affiliation":[{"name":"1Division of Hematology and Stem Cell Transplantation, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico Istituto Nazionale dei Tumori, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-5475-5161","authenticated-orcid":false,"given":"Giusy","family":"Ceparano","sequence":"additional","affiliation":[{"name":"1Division of Hematology and Stem Cell Transplantation, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico Istituto Nazionale dei Tumori, Milan, Italy"},{"name":"2Division of Hematology and Stem Cell Transplantation, University of Milan, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4453-6064","authenticated-orcid":false,"given":"Beatrice","family":"Casadei","sequence":"additional","affiliation":[{"name":"3Istituto di Ematologia \u201cSer\u00e0gnoli,\u201d Istituto di Ricovero e Cura a Carattere Scientifico Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piera","family":"Angelillo","sequence":"additional","affiliation":[{"name":"4Lymphoma Unit, Department of OncoHematology, Istituto di Ricovero e Cura a Carattere Scientifico Ospedale San Raffaele Milan, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefania","family":"Bramanti","sequence":"additional","affiliation":[{"name":"5Istituto di Ricovero e Cura a Carattere Scientifico Humanitas Research Hospital, Transplantation Unit Department of Oncology and Hematology, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Chiara","family":"Tisi","sequence":"additional","affiliation":[{"name":"6Hematology Unit, San Bortolo Hospital, Azienda Unita' Sanitaria Locale Socio Sanitaria 8 Berica, Vicenza, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1151-1477","authenticated-orcid":false,"given":"Silva","family":"Ljevar","sequence":"additional","affiliation":[{"name":"7Unit of Biostatistics for Clinical Research, Department of Data Science, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico Istituto Nazionale dei Tumori, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3401-1309","authenticated-orcid":false,"given":"Federico","family":"Stella","sequence":"additional","affiliation":[{"name":"2Division of Hematology and Stem Cell Transplantation, University of Milan, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2977-0098","authenticated-orcid":false,"given":"Annalisa","family":"Chiappella","sequence":"additional","affiliation":[{"name":"1Division of Hematology and Stem Cell Transplantation, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico Istituto Nazionale dei Tumori, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Botto","sequence":"additional","affiliation":[{"name":"8Struttura Complessa Ematologia, Azienda Ospedaliera Universitaria Citt\u00e0 della Salute e della Scienza Torino, Turin, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3721-0004","authenticated-orcid":false,"given":"Ilaria","family":"Cutini","sequence":"additional","affiliation":[{"name":"9Struttura Organizzativa Dipartimentale Terapie Cellulari e Medicina Trasfusionale, Trapianto di Midollo Osseo, Ospedale Careggi, Firenze, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giada","family":"Zanirato","sequence":"additional","affiliation":[{"name":"1Division of Hematology and Stem Cell Transplantation, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico Istituto Nazionale dei Tumori, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1355-1587","authenticated-orcid":false,"given":"Patrizia","family":"Chiusolo","sequence":"additional","affiliation":[{"name":"10Dipartimento di Scienze di Laboratorio ed Ematologiche-Fondazione Policlinico Universitario Agostino Gemelli-Istituto di Ricovero e Cura a Carattere Scientifico, Sezione di Ematologia, Dipartimento di Scienze Radiologiche ed Ematologiche, Universit\u00e0 Cattolica del Sacro Cuore, Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna Maria","family":"Barbui","sequence":"additional","affiliation":[{"name":"11Unit\u00e0 di Ematologia, Azienda Socio Sanitaria Territoriale Papa Giovanni XXIII, Bergamo, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2980-9028","authenticated-orcid":false,"given":"Mirko","family":"Farina","sequence":"additional","affiliation":[{"name":"12Unit of Blood Disease and Bone Marrow Transplantation, and Unit of Hematology, University of Brescia, Azienda Socio Sanitaria Territoriale Spedali Civili di Brescia, Brescia, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0985-9623","authenticated-orcid":false,"given":"Alice","family":"Di Rocco","sequence":"additional","affiliation":[{"name":"13Hematology, Department of Translational and Precision Medicine, Univ Sapienza Roma, Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Grillo","sequence":"additional","affiliation":[{"name":"14Dipartimento di Ematologia e trapianto di midollo, Azienda Socio Sanitaria Territoriale Grande Ospedale Metropolitano Niguarda, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2582-3500","authenticated-orcid":false,"given":"Jacopo","family":"Olivieri","sequence":"additional","affiliation":[{"name":"15Dipartimento di Clinica Ematologica, Centro Trapianti e Terapie Cellulari \u201cCarlo Melzi,\u201d Azienda Sanitaria Universitaria Integrata di Udine, Udine, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7280-2040","authenticated-orcid":false,"given":"Mauro","family":"Krampera","sequence":"additional","affiliation":[{"name":"16Hematology and Bone Marrow Transplant Unit, Section of Biomedicine of Innovation, Department of Engineering for Innovative Medicine, University of Verona, Verona, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Ladetto","sequence":"additional","affiliation":[{"name":"17Dipartimento di Medicina Traslazionale Universit\u00e0 del Piemonte Orientale ed Struttura complessa a Direzione Universitaria Ematologia Azienda Ospedaliera Universitaria SS Antonio e Biagio e Cesare Arrigo, Alessandria, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Guidetti","sequence":"additional","affiliation":[{"name":"1Division of Hematology and Stem Cell Transplantation, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico Istituto Nazionale dei Tumori, Milan, Italy"},{"name":"2Division of Hematology and Stem Cell Transplantation, University of Milan, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2112-2651","authenticated-orcid":false,"given":"Pier Luigi","family":"Zinzani","sequence":"additional","affiliation":[{"name":"3Istituto di Ematologia \u201cSer\u00e0gnoli,\u201d Istituto di Ricovero e Cura a Carattere Scientifico Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy"},{"name":"18Dipartimento di Scienze Mediche e Chirurgiche, Universit\u00e0 di Bologna, Bologna, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristiana","family":"Carniti","sequence":"additional","affiliation":[{"name":"1Division of Hematology and Stem Cell Transplantation, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico Istituto Nazionale dei Tumori, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9186-1353","authenticated-orcid":false,"given":"Paolo","family":"Corradini","sequence":"additional","affiliation":[{"name":"1Division of Hematology and Stem Cell Transplantation, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico Istituto Nazionale dei Tumori, Milan, Italy"},{"name":"2Division of Hematology and Stem Cell Transplantation, University of Milan, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2025,12,12]]},"reference":[{"issue":"11","key":"2025122309411680700_bib1","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1182\/blood.2022015851","article-title":"The international consensus classification of mature lymphoid neoplasms: a report from the Clinical Advisory Committee","volume":"140","author":"Campo","year":"2022","journal-title":"Blood"},{"issue":"12","key":"2025122309411680700_bib2","doi-asserted-by":"crossref","first-page":"e609","DOI":"10.1016\/S2352-3026(18)30177-7","article-title":"Dose-adjusted EPOCH-R (etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab) in untreated aggressive diffuse large B-cell lymphoma with MYC rearrangement: a prospective, multicentre, single-arm phase 2 study","volume":"5","author":"Dunleavy","year":"2018","journal-title":"Lancet Haematol"},{"issue":"9","key":"2025122309411680700_bib3","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1016\/j.annonc.2020.05.016","article-title":"Favourable outcomes for high-risk diffuse large B-cell lymphoma (IPI 3-5) treated with front-line R-CODOX- M\/R-IVAC chemotherapy: results of a phase 2 UK NCRI trial","volume":"31","author":"McMillan","year":"2020","journal-title":"Ann Oncol"},{"issue":"2","key":"2025122309411680700_bib4","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1111\/bjh.16319","article-title":"Poor outcomes for double-hit lymphoma patients treated with curative-intent second-line immunochemotherapy following failure of intensive front-line immunochemotherapy","volume":"189","author":"Landsburg","year":"2020","journal-title":"Br J Haematol"},{"issue":"26","key":"2025122309411680700_bib5","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N Engl J Med"},{"issue":"1","key":"2025122309411680700_bib6","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1056\/NEJMoa1804980","article-title":"Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma","volume":"380","author":"Schuster","year":"2019","journal-title":"N Engl J Med"},{"issue":"10254","key":"2025122309411680700_bib7","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/S0140-6736(20)31366-0","article-title":"Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study","volume":"396","author":"Abramson","year":"2020","journal-title":"The Lancet"},{"issue":"27","key":"2025122309411680700_bib8","doi-asserted-by":"crossref","first-page":"3119","DOI":"10.1200\/JCO.19.02104","article-title":"Standard-of-care axicabtagene ciloleucel for relapsed or refractory large B-cell lymphoma: results from the US Lymphoma CAR T Consortium","volume":"38","author":"Nastoupil","year":"2020","journal-title":"J Clin Oncol"},{"issue":"10","key":"2025122309411680700_bib9","doi-asserted-by":"crossref","first-page":"2500","DOI":"10.1182\/bloodadvances.2024014732","article-title":"Outcome of high-grade B-cell lymphoma compared to other large B-cell lymphoma after CAR-T rescue: a DESCAR-T LYSA study","volume":"9","author":"Phina-Ziebin","year":"2025","journal-title":"Blood Adv"},{"issue":"15","key":"2025122309411680700_bib12","doi-asserted-by":"crossref","first-page":"3378","DOI":"10.1158\/1078-0432.CCR-22-0164","article-title":"Phenotypic composition of commercial anti-CD19 CAR T-cells affects in vivo expansion and disease response in patients with large B-cell lymphoma","volume":"28","author":"Monfrini","year":"2022","journal-title":"Clin Cancer Res"},{"issue":"5","key":"2025122309411680700_bib13","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1097\/00001648-200009000-00011","article-title":"Marginal structural models and causal inference in epidemiology","volume":"11","author":"Robins","year":"2000","journal-title":"Epidemiology"},{"issue":"9","key":"2025122309411680700_bib14","doi-asserted-by":"crossref","first-page":"2920","DOI":"10.1182\/bloodadvances.2021005953","article-title":"Results of a United Kingdom real-world study of polatuzumab vedotin, bendamustine, and rituximab for relapsed\/refractory DLBCL","volume":"6","author":"Northend","year":"2022","journal-title":"Blood Adv"},{"issue":"12","key":"2025122309411680700_bib15","doi-asserted-by":"crossref","first-page":"2872","DOI":"10.1182\/bloodadvances.2022009019","article-title":"Effective bridging therapy can improve CD19 CAR-T outcomes while maintaining safety in patients with large B-cell lymphoma","volume":"7","author":"Roddie","year":"2023","journal-title":"Blood Adv"},{"issue":"140","key":"2025122309411680700_bib16","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1182\/blood.2020008374","article-title":"Defining and treating high-grade B-cell lymphoma, NOS","volume":"9","author":"Olszewski","year":"2022","journal-title":"Blood"},{"issue":"4","key":"2025122309411680700_bib17","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1200\/JCO.21.02143","article-title":"Impact of TP53 genomic alterations in large B-cell lymphoma treated with CD19-chimeric antigen receptor T-cell therapy","volume":"40","author":"Shouval","year":"2022","journal-title":"J Clin Oncol"},{"issue":"7","key":"2025122309411680700_bib18","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1056\/NEJMoa2116133","article-title":"Axicabtagene ciloleucel as second-line therapy for large B-cell lymphoma","volume":"386","author":"Locke","year":"2022","journal-title":"N Engl J Med"},{"issue":"4","key":"2025122309411680700_bib19","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1038\/s41591-022-01731-4","article-title":"Axicabtagene ciloleucel as first-line therapy in high-risk large B-cell lymphoma: the phase 2 ZUMA-12 trial","volume":"28","author":"Neelapu","year":"2022","journal-title":"Nat Med"},{"issue":"23","key":"2025122309411680700_bib20","doi-asserted-by":"crossref","first-page":"6073","DOI":"10.3390\/cancers13236073","article-title":"Transformed lymphoma is associated with a favorable response to CAR-T-cell treatment in DLBCL patients","volume":"13","author":"Nydegger","year":"2021","journal-title":"Cancers"},{"issue":"19","key":"2025122309411680700_bib21","doi-asserted-by":"crossref","first-page":"2621","DOI":"10.1182\/blood.2020007445","article-title":"Tumor interferon signaling and suppressive myeloid cells are associated with CAR T-cell failure in large B-cell lymphoma","volume":"137","author":"Jain","year":"2021","journal-title":"Blood"},{"issue":"9","key":"2025122309411680700_bib22","doi-asserted-by":"crossref","first-page":"2667","DOI":"10.1038\/s41591-024-03084-6","article-title":"A systematic review and meta-analysis of nonrelapse mortality after CAR T cell therapy","volume":"30","author":"Cordas Dos Santos","year":"2024","journal-title":"Nat Med"},{"issue":"4","key":"2025122309411680700_bib23","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1038\/s41591-024-02826-w","article-title":"T-cell lymphoma and secondary primary malignancy risk after commercial CAR T cell therapy","volume":"30","author":"Ghilardi","year":"2024","journal-title":"Nat Med"},{"issue":"4","key":"2025122309411680700_bib24","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1111\/bjh.19590","article-title":"Secondary primary malignancies after CD-19 directed CAR-T-cell therapy in lymphomas: a report from the Italian CART-SIE study","volume":"205","author":"Barone","year":"2024","journal-title":"Br J Haematol"},{"issue":"24","key":"2025122309411680700_bib25","doi-asserted-by":"crossref","first-page":"2584","DOI":"10.1182\/blood.2022016945","article-title":"Outcomes of patients with aggressive B-cell lymphoma after failure of anti-CD19 CAR T-cell therapy: a DESCAR-T analysis","volume":"140","author":"Di Blasi","year":"2022","journal-title":"Blood"},{"issue":"12","key":"2025122309411680700_bib26","doi-asserted-by":"crossref","first-page":"2657","DOI":"10.1182\/bloodadvances.2022008240","article-title":"Peri-CAR-T practice patterns and survival predictors for all CAR-T patients and post-CAR-T failure in aggressive B-NHL","volume":"7","author":"Zurko","year":"2023","journal-title":"Blood Adv"},{"issue":"1","key":"2025122309411680700_bib27","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1038\/s41375-022-01739-2","article-title":"Outcomes of first therapy after CD19-CAR-T treatment failure in large B-cell lymphoma","volume":"37","author":"Alarcon Tomas","year":"2023","journal-title":"Leukemia"},{"issue":"1","key":"2025122309411680700_bib28","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1111\/bjh.19057","article-title":"Outcome after chimeric antigen receptor (CAR) T-cell therapy failure in large B-cell lymphomas","volume":"204","author":"Dodero","year":"2024","journal-title":"Br J Haematol"},{"issue":"10","key":"2025122309411680700_bib29","doi-asserted-by":"crossref","first-page":"3214","DOI":"10.1002\/cam4.3881","article-title":"Real-world evidence of tisagenlecleucel for the treatment of relapsed or refractory large B-cell lymphoma","volume":"10","author":"Iacoboni","year":"2021","journal-title":"Cancer Med"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/9\/24\/6491\/2475215\/blooda_adv-2025-016117-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/9\/24\/6491\/2475215\/blooda_adv-2025-016117-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,23]],"date-time":"2025-12-23T14:41:25Z","timestamp":1766500885000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/9\/24\/6491\/546491\/Outcomes-of-CAR-T-cell-therapy-in-high-grade-B"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,12]]},"references-count":27,"journal-issue":{"issue":"24","published-print":{"date-parts":[[2025,12,23]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2025016117","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,12,23]]},"published":{"date-parts":[[2025,12,12]]}}}